Dr. Daniel J. Drucker
Medicine at the University
Biography & Research Background
Daniel J. Drucker, OC, MD, FRSC, is a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Professor of Medicine at the University of Toronto. Dr. Drucker is the discoverer of the intestinotrophic properties of glucagon-like peptide-2 (GLP-2) and his foundational 1996 publications in Nature Biotechnology and PNAS established the scientific basis for teduglutide’s development. He is one of the world’s leading authorities on incretin biology, with over 800 publications and numerous awards including the Canada Gairdner International Award and the Banting Medal for Scientific Achievement. Daniel J. Drucker is being referenced as one of the leading scientists involved in the research and development of GLP-2 Analog (Teduglutide). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Daniel J. Drucker is referenced as a leading researcher in the following peptide research profiles on SHR3D Aminos:
Dr. Daniel J. Drucker is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.